Dechert LLP is well-placed to advise clients engaged in major cross-border transactions, including assisting with patent strategies tied to deals. On the contentious front, the firm’s litigators represent clients in patent disputes tied to a variety of drugs, and are also well versed in handling MDLs and class actions arising out of product liability claims. Boston-based patent specialist Andrea Reid advises biotech and pharmaceutical clients on the management of their IP portfolios, offering a deep understanding of the drug discovery and development processes and leading the practice alongside New York’s David Rosenthal, who advises life sciences-focused investors on IPOs, secondary offerings and licensing matters. Also based in New York, litigator Katherine Helm handles a broad spectrum of patent-related disputes, representing both plaintiffs and defendants in infringement suits and tackling commercial issues including breach of contract and antitrust litigations.
Testimonials
Collated independently by Legal 500 research team.
- 'The collective discipline, first-hand knowledge of particular issues and the patience to explain complex issues is what makes the team invaluable.'
Key clients
- 4E Therapeutics
- AbbVie/Allergan
- Aldeyra Therapeutics
- argenx SE
- Atlas Ventures
- Bicycle Therapeutics
- Biogen
- Cerus Endovascular
- Chiesi Farmaceutici S.p.A.
- Dana-Farber Cancer Institute
- Diffusion Pharmaceuticals
- Eli Lilly and Company
- Endo Pharmaceuticals
- Forbion Capital Partners
- GlaxoSmithKline
- Homology Medicines
- Ikena Oncology
- Ipsen
- Johnson & Johnson
- Longwood Fund
- Moderna Therapeutics
- Nimbus Therapeutics
- Sanofi SA
- Solu Therapeutics
- Quest Diagnostics
Work highlights
- Advised Nimbus Therapeutics’ on patent issues relating to highly selective, allosteric TYK2 inhibitor portfolio to address multiple immune-mediated diseases.
- Represented GSK as lead counsel in connection with multidistrict and state court litigation alleging that Zantac, a type of heartburn medication, causes cancer as a result of the formation of the chemical NDMA.
- Advised Chiesi Farmaceutici S.p.A. in its definitive agreement to acquire Amryt Pharma Plc in an all-cash transaction valued at US$1.48bn.
Lawyers
Practice head
The lawyer(s) leading their teams.
Andrea Reid, David Rosenthal